Connor Clark & Lunn Investment Management Ltd. raised its holdings in Corvus Pharmaceuticals Inc (NASDAQ:CRVS) by 9.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,325 shares of the company’s stock after acquiring an additional 5,374 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.22% of Corvus Pharmaceuticals worth $241,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Millennium Management LLC grew its holdings in shares of Corvus Pharmaceuticals by 61.2% during the fourth quarter. Millennium Management LLC now owns 60,248 shares of the company’s stock worth $221,000 after purchasing an additional 22,878 shares during the last quarter. Bank of America Corp DE lifted its stake in Corvus Pharmaceuticals by 32.0% in the fourth quarter. Bank of America Corp DE now owns 80,281 shares of the company’s stock valued at $294,000 after buying an additional 19,451 shares during the period. Geode Capital Management LLC lifted its stake in Corvus Pharmaceuticals by 19.0% in the fourth quarter. Geode Capital Management LLC now owns 152,361 shares of the company’s stock valued at $559,000 after buying an additional 24,322 shares during the period. Fosun International Ltd lifted its stake in Corvus Pharmaceuticals by 7.5% in the first quarter. Fosun International Ltd now owns 170,974 shares of the company’s stock valued at $669,000 after buying an additional 11,992 shares during the period. Finally, Deutsche Bank AG lifted its stake in Corvus Pharmaceuticals by 304.0% in the fourth quarter. Deutsche Bank AG now owns 207,782 shares of the company’s stock valued at $762,000 after buying an additional 156,346 shares during the period. Hedge funds and other institutional investors own 82.83% of the company’s stock.
In related news, Director Peter A. Thompson acquired 32,923 shares of the company’s stock in a transaction that occurred on Thursday, June 27th. The shares were acquired at an average price of $3.34 per share, with a total value of $109,962.82. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Richard A. Md Miller acquired 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were bought at an average cost of $3.56 per share, for a total transaction of $26,700.00. The disclosure for this purchase can be found here. Insiders have bought a total of 840,423 shares of company stock valued at $3,082,705 in the last quarter. 40.40% of the stock is owned by corporate insiders.
Several equities analysts have issued reports on the company. Zacks Investment Research raised Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 15th. Mizuho initiated coverage on Corvus Pharmaceuticals in a research note on Wednesday. They issued a “buy” rating and a $7.00 price target on the stock. Finally, Roth Capital initiated coverage on Corvus Pharmaceuticals in a research report on Wednesday, May 29th. They set a “buy” rating and a $6.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $7.19.
NASDAQ CRVS traded down $0.09 on Friday, reaching $3.72. The company had a trading volume of 2,259 shares, compared to its average volume of 89,134. The company’s fifty day moving average is $3.87 and its 200 day moving average is $4.18. Corvus Pharmaceuticals Inc has a 52-week low of $3.20 and a 52-week high of $10.64. The company has a current ratio of 9.17, a quick ratio of 9.17 and a debt-to-equity ratio of 0.03.
Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.02). On average, analysts predict that Corvus Pharmaceuticals Inc will post -1.59 EPS for the current fiscal year.
Corvus Pharmaceuticals Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Featured Story: Trading based on a resistance level
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.